Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).

VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.

Share this video  

IMW 2019 | Serum BCMA: a new prognostic marker for PFS in myeloma

James Berenson • 14 Sep 2019
IMW 2019
Multiple Myeloma

James Berenson, MD, from The Institute for Myeloma & Bone Cancer Research, West Hollywood, CA, speaks at the International Myeloma Workshop (IMW) 2019, held in Boston, MA, about monitoring serum BCMA levels to indicate prognosis in multiple myeloma.

More from James Berenson

Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
2:30
Transforming patient outcomes in myeloma through real-time, SMS-based monitoring of symptoms & QoL
James Berenson • 6 Dec 2025
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
1:16
The addition of isatuximab to KRd improves transplant outcomes for patients with multiple myeloma
James Berenson • 14 Dec 2023
Medical writing bias in myeloma clinical research
1:09
Medical writing bias in myeloma clinical research
James Berenson • 11 Dec 2023
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
2:07
Addition of lenalidomide to patients with myeloma progressing on ruxolitinib and methylprednisolone
James Berenson • 11 Dec 2023

Related Videos

Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
4:32
Updated results from the iMMagine-1 trial of anito-cel in R/R multiple myeloma
James Berenson • 18 Dec 2025
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
3:36
Investigating AZD0120, a dual-targeting CAR-T product, in R/R myeloma: DURGA-1 preliminary results
James Berenson • 7 Dec 2025
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
3:11
A Phase II trial investigating IberKDd in R/R multiple myeloma: the ReKInDLE study
James Berenson • 7 Dec 2025
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
4:04
Remote therapeutic monitoring reduces infection-related hospitalizations in hematologic cancers
James Berenson • 15 Dec 2025
The content of VJHemOnc is intended for healthcare professionals